1
Country: UK | Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
2
Country: USA | Funding: $573.1M
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
3
Country: USA | Funding: $457.1M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
4
Country: USA | Funding: $426.1M
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
5
Country: USA | Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
6
Country: USA | Funding: $54.4M
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
7
Country: Italy | Funding: $35.6M
We design and develop the world's smallest and most accurate wearable devices for medical research and epilepsy management.
We design and develop the world's smallest and most accurate wearable devices for medical research and epilepsy management.
8
Country: Australia | Funding: AUD$34M
Seer is a medical technology company that specializes in addressing neurological conditions. It created at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
Seer is a medical technology company that specializes in addressing neurological conditions. It created at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
9
Country: USA | Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
10
Country: Netherlands
LivAssured develops NightWatch - the armband that notifies caregivers remotely of nightly epileptic seizures.
LivAssured develops NightWatch - the armband that notifies caregivers remotely of nightly epileptic seizures.
11
Country: India
TerraBlue XT develops epilepsy-glove that predicts the onset of epilepsy so that patients could be provided with an early intervention, helps doctors make data-driven decisions, instead of assumption-driven ones, enabling them to check the efficacy of medications.
TerraBlue XT develops epilepsy-glove that predicts the onset of epilepsy so that patients could be provided with an early intervention, helps doctors make data-driven decisions, instead of assumption-driven ones, enabling them to check the efficacy of medications.
